Donald Trump’s election victory comes weeks after the FDA named a new leader for the medical device center and as the ...

CFO Joel Grade told investors Friday that Baxter expects an approximately $200 million hit to sales in the fourth quarter ...

Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

Poul will take over the company in January after spending 11 years with 3M and working at Medtronic and Boston Scientific.

CEO Bernd Montag said the company is well positioned for a “U.S. versus China situation” that could arise when Donald Trump ...

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. Here’s what the results mean for the ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups look to build on former ...

Study author Philippe Genereux said the trial data “shatter 60 years of ingrained belief on the treatment for severe aortic ...